// App-Quantinova.ai

: Phase II trial of lurbinectedin combined with avelumab as maintenance therapy for metastatic urothelial carcinoma with stable or responding disease following platinum-based chemotherapy.

Researchers

Presenter

  • Guru P. Sonpavde

Principal Investigators

  • Carlos A. Alemany

  • Wassim Mchayleh

  • Julie W. Pepe

  • Susan Coakley

  • Ashley Young

  • Rohit K. Jain

Medical Centers

  • AdventHealth Cancer Institute, Orlando, FL

  • H. Lee Moffitt Cancer Center & Research Institute, Riverview, FL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Advanced Urothelial Carcinoma

  • Solid malignancies

Biomarkers

  • Programmed death-ligand 1

  • Granulocyte colony-stimulating factor

Drug/Treatment

  • Filgrastim

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lurbinectedin

  • Avelumab

Outcome

  • N/A

Study Design

  • Randomized

  • Multicenteric

Phase

  • II

Study Id's

  • NCT05574504

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved